HAEMONETICS CORP — Director's Dealing 2016

Jul 1, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2016-06-29

Reporting Person: Simon, Christopher (President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-29	Common Stock	A	45867	$.01	Acquired	45867	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-29	Non-qualified Stock Option (Right to Buy)	$28.615	A	196746	Acquired	2023-06-29	Common Stock (196746)	Direct
2016-06-29	Performance Shares	$0	A	26210	Acquired	2019-12-31	Common Stock (26210)	Direct
2016-06-29	Performance Shares	$0	A	65525	Acquired	2019-12-31	Common Stock (65525)	Direct

Footnotes

F1: Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.

F2: Grants of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.

F3: This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on measurements of Haemonetics' financial and operational performance. The number of Performance Share Units (and therefore the number of shares payable) will depend on performance during Haemonetics' 2017, 2018 and 2019 fiscal years. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could be up to 150% of the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.

F4: This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to companies in the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance during a three year period beginning April 3, 2016. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.